irinotecan has been researched along with gastrin-releasing peptide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aigner, E; Block, NL; Buchholz, S; Datz, C; Hohla, F; Krishan, A; Perez, R; Rick, FG; Schally, AV; Seitz, S; Stadlmayr, A; Szalontay, L | 1 |
| Chen, JP; Chuang, CC; Lan, YH; Lu, YJ; Weng, YL | 1 |
2 other study(ies) available for irinotecan and gastrin-releasing peptide
| Article | Year |
|---|---|
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
Topics: Animals; Antineoplastic Agents; Bombesin; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gastrin-Releasing Peptide; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Peptide Fragments; Receptors, Bombesin; Transplantation, Heterologous | 2012 |
Targeted delivery of irinotecan and SLP2 shRNA with GRP-conjugated magnetic graphene oxide for glioblastoma treatment.
Topics: Animals; Cell Line, Tumor; DNA; Drug Delivery Systems; Gastrin-Releasing Peptide; Glioblastoma; Graphite; Irinotecan; Ligands; Magnesium Oxide; Magnetic Phenomena; Mice; Mice, Nude; RNA, Small Interfering | 2022 |